Literature DB >> 33634992

SARS-CoV-2-related IFITM3 in immune dysfunction and tumor microenvironment: An integrative analysis in pan-cancers.

Xue-Ping Li1,2, Xin Huang2,3, Yan-Mei Qin4, Guo-Yan Wu5, Cheng-Cai Liang2,6, Yu-Jun Dai1,2, Wei-Na Zhang7.   

Abstract

Entities:  

Year:  2021        PMID： 33634992      PMCID： PMC7901722          DOI： 10.1002/ctm2.345

Source DB:  PubMed          Journal:  Clin Transl Med        ISSN： 2001-1326


× No keyword cloud information.
  10 in total

1.  Identification of Residues Controlling Restriction versus Enhancing Activities of IFITM Proteins on Entry of Human Coronaviruses.

Authors:  Xuesen Zhao; Mohit Sehgal; Zhifei Hou; Junjun Cheng; Sainan Shu; Shuo Wu; Fang Guo; Sylvain J Le Marchand; Hanxin Lin; Jinhong Chang; Ju-Tao Guo
Journal:  J Virol       Date:  2018-02-26       Impact factor: 5.103

2.  Poor clinical outcomes for patients with cancer during the COVID-19 pandemic.

Authors:  Liang V Tang; Yu Hu
Journal:  Lancet Oncol       Date:  2020-05-29       Impact factor: 41.316

3.  Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID-19 in Hubei, China: a multicentre, retrospective, cohort study.

Authors:  Kunyu Yang; Yuhan Sheng; Chaolin Huang; Yang Jin; Nian Xiong; Ke Jiang; Hongda Lu; Jing Liu; Jiyuan Yang; Youhong Dong; Dongfeng Pan; Chengrong Shu; Jun Li; Jielin Wei; Yu Huang; Ling Peng; Mengjiao Wu; Ruiguang Zhang; Bian Wu; Yuhui Li; Liqiong Cai; Guiling Li; Tao Zhang; Gang Wu
Journal:  Lancet Oncol       Date:  2020-05-29       Impact factor: 41.316

4.  Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes.

Authors:  Daniel E Leisman; Lukas Ronner; Rachel Pinotti; Matthew D Taylor; Pratik Sinha; Carolyn S Calfee; Alexandre V Hirayama; Fiore Mastroiani; Cameron J Turtle; Michael O Harhay; Matthieu Legrand; Clifford S Deutschman
Journal:  Lancet Respir Med       Date:  2020-10-16       Impact factor: 30.700

5.  Comprehensive analysis of two potential novel SARS-CoV-2 entries, TMPRSS2 and IFITM3, in healthy individuals and cancer patients.

Authors:  Yu-Jun Dai; Wei-Na Zhang; Wei-Da Wang; Si-Yuan He; Cheng-Cai Liang; Da-Wei Wang
Journal:  Int J Biol Sci       Date:  2020-09-30       Impact factor: 6.580

6.  Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.

Authors:  Wenhua Liang; Weijie Guan; Ruchong Chen; Wei Wang; Jianfu Li; Ke Xu; Caichen Li; Qing Ai; Weixiang Lu; Hengrui Liang; Shiyue Li; Jianxing He
Journal:  Lancet Oncol       Date:  2020-02-14       Impact factor: 41.316

7.  Association of COVID-19 global distribution and environmental and demographic factors: An updated three-month study.

Authors:  Mohammad Sarmadi; Nilufar Marufi; Vahid Kazemi Moghaddam
Journal:  Environ Res       Date:  2020-05-29       Impact factor: 6.498

Review 8.  Predictive monitoring and therapeutic immune biomarkers in the management of clinical complications of COVID-19.

Authors:  Hamed Fouladseresht; Mehrnoosh Doroudchi; Najmeh Rokhtabnak; Hossein Abdolrahimzadehfard; Amir Roudgari; Golnar Sabetian; Shahram Paydar
Journal:  Cytokine Growth Factor Rev       Date:  2020-10-09       Impact factor: 7.638
  10 in total
  1 in total

1.  Identification of potential modulators of IFITM3 by in-silico modeling and virtual screening.

Authors:  Vikas Tiwari; Shruthi Viswanath
Journal:  Sci Rep       Date:  2022-09-24       Impact factor: 4.996
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.